Plimasin* is a new antiallergic preparation, combining 25 mg. of tripelennamine HCl (Pyribenzamine, Ciba) and 5 mg. of methyl-phenidylacetate (Ritalin, Ciba). The combination was originally used to determine whether it eliminated antihistaminic side-effects, such as drowsiness, which bother some patients. Preliminary European trials seemed to indicate that smaller doses of the antihistamine were effective when administered in Plimasin. This study is a preliminary evaluation of its effectiveness in skin conditions with special reference to its therapeutic indications.
Methyl-phenidylacetate (methyl phenyl-2piperidineacetate hydrochloride), a new synthetic compound, has a marked psychomotor stimulating effect, similar to the effect known for some phenylisopropylamines. Subcutaneous injection of 1 to 2 mg/kg. in experimental animals stimulates respiration and increases motility considerably. Its clinical effect suggests in part amphetamine, but differs from it and must be classified between it and caffeine.
This survey covers 193 successive cases
KUHN BH. Plimasin: A Preliminary Evaluation. AMA Arch Derm. 1955;72(1):59–62. doi:10.1001/archderm.1955.03730310061012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: